Vical, Inc. (NASDAQ:VICL)

CAPS Rating: 4 out of 5

The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

Results 1 - 20 of 28 : 1 2 Next »

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 3/18/2014 7:03:47 PM : Outperform Start Price: $1.32 VICL Score: -20.34

prediction TOS

Recs

0
Member Avatar 10qdetective (36.50) Submitted: 3/4/2014 1:45:46 AM : Outperform Start Price: $1.51 VICL Score: -37.18

Potential buyer in Merck?

Vical (VICL) is developing Allovectin, a first-in-class investigational DNA-based immunotherapeutic designed to stimulate both innate and adaptive immune responses in local tumors and distal metastases.

Of unique interest to Merck is that this immunotherapy is currently being evaluated in late-stage clinical trials as first-line treatment for Stage III and IV melanoma. Merck watchers might want to know, too, that Vical’s current CEO, Vijay Samant, previously spent 20 years with Merck in international sales and marketing.

Recs

0
Member Avatar paigecoverdale (< 20) Submitted: 1/13/2014 3:38:31 PM : Outperform Start Price: $1.32 VICL Score: -30.37

Doubler

Recs

1
Member Avatar AndrewGreenBull (99.04) Submitted: 12/18/2013 11:37:30 AM : Outperform Start Price: $1.05 VICL Score: -10.51

With 2 approved products, a robust pipeline and 55 millions cash, VICL is a steal at current price $1.04.

Dengue Vaccine data will be released in this month according to ClinicalTrial. Should be back to $2 in days.

Recs

0
Member Avatar Rilac (98.26) Submitted: 9/5/2013 4:48:36 PM : Outperform Start Price: $1.50 VICL Score: -48.76

Vical is posed for a pullback as the dates for their clinical trials in phase2/3 studies nears

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/22/2013 5:22:16 PM : Underperform Start Price: $1.35 VICL Score: +44.11

Short. Revenues declining. POS biotech.

Recs

6
Member Avatar zzlangerhans (99.85) Submitted: 8/12/2013 10:35:03 AM : Outperform Start Price: $1.51 VICL Score: -49.62

Screech! Flipturn!

I won't bother to gloat about Vical's faceplant, since I misjudged the degree of the drop myself and missed out on the opportunity to make money on puts. However, if anyone is in the mood for schadenfreude check out the comments on this article www.fool.com/investing/general/2013/07/08/why-vical-is-poised-to-pull-back.aspx

The more angry, grammatically-challenged, plodding rebuttals appear after these articles, the more likely it is that I'll turn out to be right. It's like a big balloon of stupid levitating the share prices of doomed stocks like Vical. However, when that balloon pops the stock drops hard and irrational optimism is immediately replaced by irrational pessimism. Vical just reported a cash position of 70M and they have a phase III trial of CMV vaccine TransVax in hematopoietic cell transplants already in progress. A phase II trial of TransVax in solid organ transplant recipients and a phase I/II trial of a herpes vaccine are planned to begin later this year as well. The prospects for these vaccines are questionable at best but their value is undoubtedly more than the 50M enterprise value of Vical at a share price of 1.41, which is where I purchased 10000 shares today in the pre-market for the zzporte collaboration. Let the TransVax pumping begin!

Recs

0
Member Avatar carsondyle (76.79) Submitted: 11/3/2012 6:09:50 AM : Outperform Start Price: $3.17 VICL Score: -116.44

"Come on, baby needs a new pair of shoes" Bio spec. Company has products they are selling, insiders buying shares, making deals with BMS, only has around 300 mil market cap, it's priced like a preclinical biotech with dubious products but they are already selling products and have a cancer drug in late stage 3 development. I think this stock is worth double what it's selling for without a successful outcome for the stage 3 trial. But thats up to Mr Market.

Recs

0
Member Avatar stainsolution (42.35) Submitted: 4/9/2012 7:42:06 PM : Outperform Start Price: $3.17 VICL Score: -115.50

Bio play

Recs

0
Member Avatar RBuskey106 (47.05) Submitted: 3/14/2012 10:43:51 PM : Outperform Start Price: $3.36 VICL Score: -115.15

Biotech play. Like the story.

Recs

0
Member Avatar CATMANF800 (< 20) Submitted: 12/3/2011 2:51:12 PM : Outperform Start Price: $4.78 VICL Score: -140.48

Technicals

Recs

0
Member Avatar vaderblue (< 20) Submitted: 11/23/2011 4:24:47 PM : Outperform Start Price: $3.45 VICL Score: -146.24

I feel Vical will outperform with needed cash coming from a vaccine recently licensed to Astellas Pharna of Japan. This will improve their revenue as well as the
balance sheet. A hurdle over the hump. I can see
$5 or more within two quarters. Go go long.

Recs

0
Member Avatar qasamm (35.72) Submitted: 4/5/2011 2:32:51 PM : Outperform Start Price: $2.97 VICL Score: -118.12

Pipeline, pipeline, pipeline- the 3 Ps!

Recs

0
Member Avatar drivermike64 (86.48) Submitted: 3/14/2011 1:36:28 AM : Outperform Start Price: $2.42 VICL Score: -113.87

biotech with promising cancer drug in stage III trials

Recs

0
Member Avatar chimpcontest (< 20) Submitted: 2/21/2011 2:11:28 PM : Outperform Start Price: $1.89 VICL Score: -97.25

BlackSwanCapital haiku

Third phase data soon

immunotherapeutic

a wunderkind drug

Recs

0
Member Avatar DudeManBroChief (< 20) Submitted: 9/30/2010 12:32:13 PM : Outperform Start Price: $2.21 VICL Score: -131.80

Look for this stock to spike in mid-2011 before results are revealed for the phase III trial of Allovectin-7 in melanoma.

Recs

0
Member Avatar BicaChica (78.88) Submitted: 9/29/2010 10:11:54 PM : Outperform Start Price: $2.26 VICL Score: -131.36

tenmiles

Recs

0
Member Avatar leebest1a (< 20) Submitted: 8/1/2010 3:51:11 PM : Outperform Start Price: $3.40 VICL Score: -152.76

VICL

Recs

0
Member Avatar Biotech2010 (49.52) Submitted: 1/26/2010 8:50:26 PM : Outperform Start Price: $2.91 VICL Score: -152.05

@3.41

Recs

0
Member Avatar colbob2 (< 20) Submitted: 12/3/2009 5:22:50 PM : Outperform Start Price: $2.90 VICL Score: -147.38

AS A PHARMACIST I FEEL THE FUTURE IN DRUGS IS IN THE VACINE FIELD, WHICH VICL EXCELS. WITH MONEY FROM MERCK, AND SNY. I FEEL THAT THIS STOCK WILL MOVE UP NEXT YEAR AND FEEL THAT THE SELL OFF THAT IS NOW GOING ON IS A TAX RELIEF SELL OFF.

Results 1 - 20 of 28 : 1 2 Next »

Featured Broker Partners


Advertisement